116 related articles for article (PubMed ID: 12372512)
21. Noncataleptogenic, centrally acting dopamine D-2 and serotonin 5-HT2 antagonists within a series of 3-substituted 1-(4-fluorophenyl)-1H-indoles.
Perregaard J; Arnt J; Bøgesø KP; Hyttel J; Sánchez C
J Med Chem; 1992 Mar; 35(6):1092-101. PubMed ID: 1348090
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and characterization of selective dopamine D2 receptor antagonists. 2. Azaindole, benzofuran, and benzothiophene analogs of L-741,626.
Vangveravong S; Taylor M; Xu J; Cui J; Calvin W; Babic S; Luedtke RR; Mach RH
Bioorg Med Chem; 2010 Jul; 18(14):5291-300. PubMed ID: 20542439
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors.
Campiani G; Butini S; Trotta F; Fattorusso C; Catalanotti B; Aiello F; Gemma S; Nacci V; Novellino E; Stark JA; Cagnotto A; Fumagalli E; Carnovali F; Cervo L; Mennini T
J Med Chem; 2003 Aug; 46(18):3822-39. PubMed ID: 12930145
[TBL] [Abstract][Full Text] [Related]
24. Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.
Kołaczkowski M; Marcinkowska M; Bucki A; Śniecikowska J; Pawłowski M; Kazek G; Siwek A; Jastrzębska-Więsek M; Partyka A; Wasik A; Wesołowska A; Mierzejewski P; Bienkowski P
Eur J Med Chem; 2015 Mar; 92():221-35. PubMed ID: 25557493
[TBL] [Abstract][Full Text] [Related]
25. Synthesis, SAR and pharmacology of CP-293,019: a potent, selective dopamine D4 receptor antagonist.
Sanner MA; Chappie TA; Dunaiskis AR; Fliri AF; Desai KA; Zorn SH; Jackson ER; Johnson CG; Morrone JM; Seymour PA; Majchrzak MJ; Faraci WS; Collins JL; Duignan DB; Prete Di CC; Lee JS; Trozzi A
Bioorg Med Chem Lett; 1998 Apr; 8(7):725-30. PubMed ID: 9871530
[TBL] [Abstract][Full Text] [Related]
26. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and structure-activity relationships of a new model of arylpiperazines. 5. Study of the physicochemical influence of the pharmacophore on 5-HT(1a)/alpha(1)-adrenergic receptor affinity: synthesis of a new derivative with mixed 5-HT(1a)/d(2) antagonist properties.
López-Rodríguez ML; Morcillo MJ; Fernández E; Porras E; Orensanz L; Beneytez ME; Manzanares J; Fuentes JA
J Med Chem; 2001 Jan; 44(2):186-97. PubMed ID: 11170628
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis, and discovery of 3-piperazinyl-3,4-dihydro-2(1H)-quinolinone derivatives: a novel series of mixed dopamine D2/D4 receptor antagonists.
Zhao H; Thurkauf A; Braun J; Brodbeck R; Kieltyka A
Bioorg Med Chem Lett; 2000 Sep; 10(18):2119-22. PubMed ID: 10999484
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and binding studies on a new series of arylpiperazino benzazol-2-one and benzoxazin-3-one derivatives as selective D4 ligands.
Carato P; Depreux P; Lesieur D; Millan M; Newman-Tancredi A; Rettori MC; Caignard DH
Drug Des Discov; 2000; 17(2):173-81. PubMed ID: 11045903
[TBL] [Abstract][Full Text] [Related]
30. Structure-affinity relationship study on N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamides as potent and selective dopamine D(3) receptor ligands.
Leopoldo M; Berardi F; Colabufo NA; De Giorgio P; Lacivita E; Perrone R; Tortorella V
J Med Chem; 2002 Dec; 45(26):5727-35. PubMed ID: 12477356
[TBL] [Abstract][Full Text] [Related]
31. Preparation and biological evaluation of indole, benzimidazole, and thienopyrrole piperazine carboxamides: potent human histamine h(4) antagonists.
Venable JD; Cai H; Chai W; Dvorak CA; Grice CA; Jablonowski JA; Shah CR; Kwok AK; Ly KS; Pio B; Wei J; Desai PJ; Jiang W; Nguyen S; Ling P; Wilson SJ; Dunford PJ; Thurmond RL; Lovenberg TW; Karlsson L; Carruthers NI; Edwards JP
J Med Chem; 2005 Dec; 48(26):8289-98. PubMed ID: 16366610
[TBL] [Abstract][Full Text] [Related]
32. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
[TBL] [Abstract][Full Text] [Related]
33. Design and synthesis of imidazoline derivatives active on glucose homeostasis in a rat model of type II diabetes. 2. Syntheses and biological activities of 1,4-dialkyl-, 1,4-dibenzyl, and 1-benzyl-4-alkyl-2-(4',5'-dihydro-1'H-imidazol-2'-yl)piperazines and isosteric analogues of imidazoline.
Le Bihan G; Rondu F; Pelé-Tounian A; Wang X; Lidy S; Touboul E; Lamouri A; Dive G; Huet J; Pfeiffer B; Renard P; Guardiola-Lemaître B; Manéchez D; Pénicaud L; Ktorza A; Godfroid JJ
J Med Chem; 1999 May; 42(9):1587-603. PubMed ID: 10229628
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and characterization of a series of chiral alkoxymethyl morpholine analogs as dopamine receptor 4 (D4R) antagonists.
Witt JO; McCollum AL; Hurtado MA; Huseman ED; Jeffries DE; Temple KJ; Plumley HC; Blobaum AL; Lindsley CW; Hopkins CR
Bioorg Med Chem Lett; 2016 May; 26(10):2481-2488. PubMed ID: 27080176
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and structure-activity relationship of the isoindolinyl benzisoxazolpiperidines as potent, selective, and orally active human dopamine D4 receptor antagonists.
Hendrix JA; Shimshock SJ; Shutske GM; Tomer JD; Kapples KJ; Palermo MG; Corbett TJ; Vargas HM; Kafka S; Brooks KM; Laws-Ricker L; Lee DK; de Lannoy I; Bordeleau M; Rizkalla G; Owolabi J; Kamboj RK
Chembiochem; 2002 Oct; 3(10):999-1009. PubMed ID: 12362366
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and biological characterization of novel hybrid 7-[[2-(4-phenyl-piperazin-1-yl)-ethyl]-propyl-amino]-5,6,7,8-tetrahydro-naphthalen-2-ol and their heterocyclic bioisosteric analogues for dopamine D2 and D3 receptors.
Dutta AK; Venkataraman SK; Fei XS; Kolhatkar R; Zhang S; Reith ME
Bioorg Med Chem; 2004 Aug; 12(16):4361-73. PubMed ID: 15265488
[TBL] [Abstract][Full Text] [Related]
37. Design and synthesis of [(2,3-dichlorophenyl)piperazin-1-yl]alkylfluorenylcarboxamides as novel ligands selective for the dopamine D3 receptor subtype.
Robarge MJ; Husbands SM; Kieltyka A; Brodbeck R; Thurkauf A; Newman AH
J Med Chem; 2001 Sep; 44(19):3175-86. PubMed ID: 11543687
[TBL] [Abstract][Full Text] [Related]
38. Design and synthesis of 2-[4-[4-(m-(ethylsulfonamido)-phenyl) piperazin-1-yl]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole (EF-7412) using neural networks. A selective derivative with mixed 5-HT1A/D2 antagonist properties.
López-Rodríguez ML; Morcillo MJ; Fernández E; Rosado ML; Orensanz L; Beneytez ME; Manzanares J; Fuentes JA; Schaper KJ
Bioorg Med Chem Lett; 1999 Jun; 9(12):1679-82. PubMed ID: 10397500
[TBL] [Abstract][Full Text] [Related]
39. Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]piperazine monomethanesulfonate (U-90152S), a second-generation clinical candidate.
Romero DL; Morge RA; Genin MJ; Biles C; Busso M; Resnick L; Althaus IW; Reusser F; Thomas RC; Tarpley WG
J Med Chem; 1993 May; 36(10):1505-8. PubMed ID: 7684450
[No Abstract] [Full Text] [Related]
40. Design, synthesis, pharmacological evaluation and computational studies of 1-(biphenyl-4-yl)-2-[4-(substituted phenyl)-piperazin-1-yl]ethanones as potential antipsychotics.
Bhosale SH; Kanhed AM; Dash RC; Suryawanshi MR; Mahadik KR
Eur J Med Chem; 2014 Mar; 74():358-65. PubMed ID: 24486417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
